- Condition: OSTEOPOROSIS, POSTMENOPAUSAL
Interventions: Drug: AMG 785 Dose 1; Drug: AMG 785 Dose 2
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Steroid-induced Osteporosis, Glucocorticoid-induced Osteporosis
Interventions: Drug: Active denosumab with placebo for risedronate; Drug: Active risedronate with placebo for denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Postmenopausal Osteoporosis
Interventions: Drug: AMG 785; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Primary Hyperparathyroidism
Interventions: Drug: Denosumab; Other: Placebo
Sponsors: Columbia University; John P. Bilezikian; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen
Recruiting - verified March 2012 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: AMG 145; Biological: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: AMG 579; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Condition: Non Hodgkin Lymphoma
Interventions: Drug: Pegfilgrastim; Drug: Filgrastim
Sponsors: Centre Leon Berard; Centre Leon Berard; Amgen
Not yet recruiting - verified February 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Condition: Early Stage Breast Cancer
Intervention: Drug: Denosumab
Sponsors: University of California, San Francisco; Hope Rugo, MD; University of California, San Francisco; Amgen
Not yet recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Behavioral: Peer Support Program
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Amgen
Recruiting - verified February 2012 - Condition: Hypercholesterolemia
Interventions: Drug: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Colorectal Cancer Metastatic; Liver Metastases; KRAS Wild Type Colorectal Cancer
Intervention: Drug: 5-FU, Folinic Acid, Oxaliplatin, Bevacizumab, Panitumumab
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Amgen; Roche Pharma AG
Not yet recruiting - verified January 2012 - Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Romiplostim
Sponsors: IRCCS San Raffaele; Andres J. M. Ferreri; Amgen
Recruiting - verified January 2012 - Condition: Asthma
Interventions: Drug: AMG 761; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Renal Cell Adenocarcinoma; Clear Cell Renal Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma
Intervention: Drug: AMG 172
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: R-CHOEP14x6+HD-AraC+HD-Mtx
Sponsors: Nordic Lymphoma Group; Nordic Lymphoma Group; Amgen
Active, not recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: AMG 479; Drug: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Not yet recruiting - verified November 2011 - Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2012 - Conditions: Chronic Renal Failure; Chronic Kidney Disease
Interventions: Biological: Epoetin Hospira; Biological: Epogen Amgen
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2012 - Condition: Renal Impairment
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Anemia; Breast Cancer; Cancer; Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Solid Tumors
Intervention:
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Advanced Malignant Glioma; Anaplastic Astrocytomas; Glioblastoma Multiforme
Intervention: Drug: AMG 595
Sponsors: Amgen; Amgen
Not yet recruiting - verified November 2011 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 876
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Chronic Kidney Disease; Hyperparathyroidism, Secondary
Intervention: Drug: Cinacalcet HCl
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011 - Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Immune Thrombocytopenic Purpura
Interventions: Biological: Eltrombopag; Biological: Romiplostim
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 820
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011 - Conditions: Anemia; Chronic Kidney Disease
Intervention: Drug: Darbepoetin alfa
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011 - Condition: Psoriasis
Intervention: Drug: AMG 557 or PLACEBO
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827; Drug: Placebo; Drug: AMG 827
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: AMG 811 or Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Enrolling by invitation - verified April 2012 - Condition: Asthma
Interventions: Drug: AMG 157 Matching Placebo; Drug: AMG 157
Sponsors: Amgen; Amgen
Not yet recruiting - verified January 2012 - Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: AMG 145; Drug: AMG 145; Drug: AMG 145; Drug: AMG 145; Drug: AMG 145; Drug: PLACEBO; Drug: PLACEBO
Sponsors: Amgen; Amgen; TIMI Study Group
Active, not recruiting - verified April 2012 - Condition: Hypercholesterolemia, Familial
Interventions: Drug: AMG 145; Drug: AMG 145; Drug: PLACEBO
Sponsors: Amgen; Amgen
Active, not recruiting - verified April 2012 - Condition: Hyperlipidemia
Interventions: Biological: AMG 145; Other: Ezetimibe; Other: Placebo
Sponsors: Amgen; Amgen
Active, not recruiting - verified April 2012 - Condition: Hyperlipidemia
Interventions: Biological: AMG 145; Other: Ezetimibe; Other: Placebo
Sponsors: Amgen; Amgen
Active, not recruiting - verified April 2012 - Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Intervention: Drug: panitumumab + docetaxel + cisplatino
Sponsors: Grupo Gallego de Investigaciones Oncologicas; Grupo Gallego de Investigaciones Oncologicas; Amgen; Trial Form Support S.L.
Recruiting - verified April 2011 - Conditions: Cancer; Hematologic Malignancies; Leukemia; Myeloid Leukemia
Interventions: Drug: Arm 1- Dose Escalation; Drug: Arm 2- Dose Expansion
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: MDS
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012
 |
Amgen - Database of Clinical Trials by Pharmaceutical Companies |
